Miquel Tarón
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Lung Cancer Research Studies, Colorectal Cancer Treatments and Studies, RNA modifications and cancer
Most-Cited Works
- → Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial(2012)5,500 cited
- → Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer(2009)2,363 cited
- → Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer(2012)1,207 cited
- Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.(2002)
- → Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer(2007)442 cited
- → FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR(2011)390 cited
- → Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients(2004)358 cited
- → Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy(2007)315 cited
- → BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer(2004)304 cited
- → Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations(2011)300 cited